Different approach to conserving therapy of uterine fibroids in women of reproductive age

Abstract

The aim of the study was to evaluate the effectiveness of integrated treatment of uterine fibroids in women of reproductive age; 103 women of reproductive age of minimally invasive myomectomy performed accesses. To prevent a recurrence of fibroids patients in Group 1 as adjuvant therapy was administered agonist of gonadotropin-releasing hormone (buserelin) prolonged action for 4-6 months, patients in group 2 did not receive anti-relapse therapy, patients of group 3 as neoadjuvant ulipristal acetate therapy received. An assessment of long-term effects in all groups of patients. The criteria for the effectiveness of treatment were: frequency of recurrence of fibroids, reproductive and normalization of menstrual function. The result is a significant increase in the recurrence of uterine fibroids in the group receiving no adjuvant therapy (5,2% vs 25%).

Keywords

• uterine fibroids
• myomectomy
• agonists of gonadotropin-releasing hormone
• ulipristal acetate